The role of regional nodal irradiation in clinically node-positive breast cancer patients who undergo neoadjuvant chemotherapy and breast-conserving surgery [0.03%]
新辅助化疗保乳术后临床阳性淋巴结乳腺癌患者的区域选择性淋巴结放射治疗作用
Mahtab Vasigh,Austin D Williams,Jill S Hasler et al.
Mahtab Vasigh et al.
Purpose: The use of neoadjuvant chemotherapy (NAC) in breast cancer management has increased, leading to uncertainties in adjuvant treatment benefits. Met...
Correction: Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer [0.03%]
对早期乳腺癌患者中PALPALLAS随机试验添加帕博西尼对持续辅助内分泌治疗依从性影响的更正公告
Eileen Shinn,David Zahrieh,Angela DeMichele et al.
Eileen Shinn et al.
Published Erratum
Breast cancer research and treatment. 2026 Feb 18;216(2):12. DOI:10.1007/s10549-026-07896-7 2026
Cost-effectiveness analysis of Mepitel Film for prevention of acute radiation dermatitis in breast cancer: a Canadian healthcare perspective [0.03%]
从加拿大医疗保健角度分析丙泊酚预防乳腺癌急性放射性皮炎的成本效益
Shirley S W Tse,Henry C Y Wong,Flay Charbonneau et al.
Shirley S W Tse et al.
Introduction: While randomized clinical trials (RCT) confirmed superiority of Mepitel Film (MF) in reducing acute radiation dermatitis (ARD) compared to standard-of-care (SoC), the incremental cost difference has limited ...
Neoadjuvant therapy with an aromatase inhibitor and durvalumab in postmenopausal patients with hormone receptor-positive breast cancer [0.03%]
绝经后激素受体阳性乳腺癌患者新辅助芳香化酶抑制剂和度伐利尤单抗治疗
Aixa E Soyano Muller,Dawn N Goodridge,Qianxing Mo et al.
Aixa E Soyano Muller et al.
Purpose: Hormone receptor-positive (HR+), HER2-negative breast cancer represents the most common subtype of breast cancer and is characterized by a risk of late recurrence. Neoadjuvant endocrine therapy with aromatase inh...
Remote symptom monitoring with clinical alerts following lumpectomy: do alerts predict 30-day re-operation or re-admission rates? [0.03%]
乳房局部切除术后远程症状监测及临床预警：预警能否预测30天内再次手术或再入院率？
Jennifer Wang,Solange Bayard,Melissa Assel et al.
Jennifer Wang et al.
Purpose: Electronic patient-reported outcomes (ePROs) are used postoperatively to detect complications through real-time symptom monitoring. This study examines whether alerts triggered through the "Recovery Tracker" (RT)...
Contrast-enhanced mammography-guided wire implantation: a cost-effective and reliable alternative for non-palpable contrast-enhanced imaging-only lesions [0.03%]
对比增强型乳房X射线摄影引导下的导丝植入：非触痛性对比增强影像病变的一种经济且可靠的选择
Hulya Ozdemir,Umur Anil Pehlivan,Huseyin Ozgur Aytac
Hulya Ozdemir
Letter to editor on the article by K.‑H. Yoon et al., titled Impact of obesity on breast cancer recurrence by menopausal status and subtype [0.03%]
关于K-HYoon等人著作《肥胖对绝经状态和亚型乳腺癌复发的影响》的来信
A N Bharani,A Prateeksha,H P Samanvay
A N Bharani
Prognostic performance of thymidine kinase 1 activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with CDK4/6 and aromatase inhibitors [0.03%]
激素受体阳性且HER2阴性的乳腺癌患者在接受CDK4/6和芳香化酶抑制剂治疗时，胸苷激酶1活性的预后价值
Nicole L Brown,Sacha J Howell,Dimitrios Papantoniou et al.
Nicole L Brown et al.
Purpose: Thymidine kinase 1 activity (TKa) has previously been demonstrated as a prognostic biomarker for progression-free survival (PFS) in hormone receptor-positive, HER2-negative metastatic breast cancer (MBC), but its...
Defining prognostic subgroups and treatment outcomes in estrogen receptor low-positive de novo metastatic breast cancer [0.03%]
定义雌激素受体低阳性初始转移性乳腺癌的预后亚组和治疗结果
Madelyn F Klugman,Maya Aboumrad,Ruizhe Chen et al.
Madelyn F Klugman et al.
Background: Prognostic factors and treatment outcomes have been identified in estrogen receptor (ER) low-positive early-stage breast cancer. This study evaluates outcomes in ER low-positive de novo metastatic breast cance...